Practitioners opted to target only the injectable dosage forms of olanzapine and benzodiazepines. This decision was made based on the more pronounced pharmacokinetic properties of the parenteral ...

Global clinical nutrition market will reach $107.65 billion by 2032, growing by 8.2% annually over 2022-2032. The growth is driven by the increasing incidence of malnutrition, the rising prevalence of ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 61 tables and 74 figures, this 149-page report ?North America Clinical Nutrition Market 2022-2032 by Substrate, ...

In this podcast episode, we discuss trends in dosage forms, specifically oral solid dosage ... of and the progress made so far by the biopharma industry toward non-parenteral means of delivering ...

A consortium of investors led by Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 15.0% during the 4th quarter, according to its most ...

Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price objective reduced by Barclays from $28.00 to $26.00 in ...

Just when you think you’ve compared insurance products thoroughly and found the absolute best one for your needs, you scroll down and realise that there are these things called ...

Merck discussed this decision to stop the HYPERION study early with the U.S. Food and Drug Administration (FDA ... therapy or change in the background PAH therapy delivery route to parenteral.

In 2023, the global sugar-based excipients market share is projected to reach USD 1,068.41 million, with a steady growth rate ...